Repros Low-Testosterone Therapy NDA May Be Delayed Until Q4 2014
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The company is preparing two head-to-head studies against approved testosterone replacement therapies to try to demonstrate Androxal’s superiority, even as apparent data fraud at a study site may alter the final analysis of a pivotal Phase III study.
You may also be interested in...
Repros Seeks To Develop Low-Dose Proellex To Avoid Liver Toxicity
In a precarious financial situation, the company requests that FDA lift a clinical hold on the drug it is developing for uterine fibroids and endometriosis.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.